fak inhibitor 14 Search Results


93
Santa Cruz Biotechnology 1 2 4 5 benzenetetraamine tetrahydrochloride
1 2 4 5 Benzenetetraamine Tetrahydrochloride, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fak+inhibitor+14/FAK+Inhibitor+14/pmc11546324-179-6-9
Average 93 stars, based on 1 article reviews
1 2 4 5 benzenetetraamine tetrahydrochloride - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

95
MedChemExpress focal adhesion kinase fak inhibitor y15
Anchorage independence is required for apical-out polarity. (A) MDCK cells were seeded into soft agar. Cells were left untreated or were treated with RhoA activator II. (B) Quantification of colonies formed in the agar assay. Each data point represents the mean (from a minimum of three field of view) from each experimental replicate (three replicate experiments were performed in total) (error bars are overall mean±s.d.). * P <0.05 (paired two-tailed t -test). (C) MDCK cysts were grown in Matrigel for 7 days and then treated with RhoA activator II for 72 h, pre-treated with FAK inhibitor <t>Y15</t> 24 h followed by Y15+Rho Activator II for an additional 48 h, or treated with Rho activator II for 24 h, followed by Y15+Rho activator II for an additional 48 h (post treatment). (D) Quantification of normal, disrupted lumen and eversion for each condition. Each data point represents the mean (expressed as a percentage) of each condition per replicate experiment (minimum of 10 cysts analyzed per condition per experiment, five replicate experiments performed in total; error bars are overall mean±s.d.). ** P <0.01; ns, not significant (two-way ANOVA with Tukey's multiple comparison test).
Focal Adhesion Kinase Fak Inhibitor Y15, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fak+inhibitor+14/Y15/pmc13405224-133-0-21
Average 95 stars, based on 1 article reviews
focal adhesion kinase fak inhibitor y15 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

94
Tocris 1 2 4 5 benzenetetramine tetrahydrochloride
Anchorage independence is required for apical-out polarity. (A) MDCK cells were seeded into soft agar. Cells were left untreated or were treated with RhoA activator II. (B) Quantification of colonies formed in the agar assay. Each data point represents the mean (from a minimum of three field of view) from each experimental replicate (three replicate experiments were performed in total) (error bars are overall mean±s.d.). * P <0.05 (paired two-tailed t -test). (C) MDCK cysts were grown in Matrigel for 7 days and then treated with RhoA activator II for 72 h, pre-treated with FAK inhibitor <t>Y15</t> 24 h followed by Y15+Rho Activator II for an additional 48 h, or treated with Rho activator II for 24 h, followed by Y15+Rho activator II for an additional 48 h (post treatment). (D) Quantification of normal, disrupted lumen and eversion for each condition. Each data point represents the mean (expressed as a percentage) of each condition per replicate experiment (minimum of 10 cysts analyzed per condition per experiment, five replicate experiments performed in total; error bars are overall mean±s.d.). ** P <0.01; ns, not significant (two-way ANOVA with Tukey's multiple comparison test).
1 2 4 5 Benzenetetramine Tetrahydrochloride, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fak+inhibitor+14/FAK+Inhibitor+14/pmc03838341-39-0-7
Average 94 stars, based on 1 article reviews
1 2 4 5 benzenetetramine tetrahydrochloride - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

92
MedChemExpress 14z
Anchorage independence is required for apical-out polarity. (A) MDCK cells were seeded into soft agar. Cells were left untreated or were treated with RhoA activator II. (B) Quantification of colonies formed in the agar assay. Each data point represents the mean (from a minimum of three field of view) from each experimental replicate (three replicate experiments were performed in total) (error bars are overall mean±s.d.). * P <0.05 (paired two-tailed t -test). (C) MDCK cysts were grown in Matrigel for 7 days and then treated with RhoA activator II for 72 h, pre-treated with FAK inhibitor <t>Y15</t> 24 h followed by Y15+Rho Activator II for an additional 48 h, or treated with Rho activator II for 24 h, followed by Y15+Rho activator II for an additional 48 h (post treatment). (D) Quantification of normal, disrupted lumen and eversion for each condition. Each data point represents the mean (expressed as a percentage) of each condition per replicate experiment (minimum of 10 cysts analyzed per condition per experiment, five replicate experiments performed in total; error bars are overall mean±s.d.). ** P <0.01; ns, not significant (two-way ANOVA with Tukey's multiple comparison test).
14z, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fak+inhibitor+14/FAK+inhibitor+2/bio_rxiv__2024__07__05__602013-257-21-22
Average 92 stars, based on 1 article reviews
14z - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

93
Tocris fak inhibitor 14
Anchorage independence is required for apical-out polarity. (A) MDCK cells were seeded into soft agar. Cells were left untreated or were treated with RhoA activator II. (B) Quantification of colonies formed in the agar assay. Each data point represents the mean (from a minimum of three field of view) from each experimental replicate (three replicate experiments were performed in total) (error bars are overall mean±s.d.). * P <0.05 (paired two-tailed t -test). (C) MDCK cysts were grown in Matrigel for 7 days and then treated with RhoA activator II for 72 h, pre-treated with FAK inhibitor <t>Y15</t> 24 h followed by Y15+Rho Activator II for an additional 48 h, or treated with Rho activator II for 24 h, followed by Y15+Rho activator II for an additional 48 h (post treatment). (D) Quantification of normal, disrupted lumen and eversion for each condition. Each data point represents the mean (expressed as a percentage) of each condition per replicate experiment (minimum of 10 cysts analyzed per condition per experiment, five replicate experiments performed in total; error bars are overall mean±s.d.). ** P <0.01; ns, not significant (two-way ANOVA with Tukey's multiple comparison test).
Fak Inhibitor 14, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fak+inhibitor+14/FAK+Inhibitor+14/wong_lian_elizabeth__2018__mechanical_signaling_and_patterning_stem_cell_derived_vascular_cells-306-24-27
Average 93 stars, based on 1 article reviews
fak inhibitor 14 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

90
Biomol GmbH fak inhibitor 14
Anchorage independence is required for apical-out polarity. (A) MDCK cells were seeded into soft agar. Cells were left untreated or were treated with RhoA activator II. (B) Quantification of colonies formed in the agar assay. Each data point represents the mean (from a minimum of three field of view) from each experimental replicate (three replicate experiments were performed in total) (error bars are overall mean±s.d.). * P <0.05 (paired two-tailed t -test). (C) MDCK cysts were grown in Matrigel for 7 days and then treated with RhoA activator II for 72 h, pre-treated with FAK inhibitor <t>Y15</t> 24 h followed by Y15+Rho Activator II for an additional 48 h, or treated with Rho activator II for 24 h, followed by Y15+Rho activator II for an additional 48 h (post treatment). (D) Quantification of normal, disrupted lumen and eversion for each condition. Each data point represents the mean (expressed as a percentage) of each condition per replicate experiment (minimum of 10 cysts analyzed per condition per experiment, five replicate experiments performed in total; error bars are overall mean±s.d.). ** P <0.01; ns, not significant (two-way ANOVA with Tukey's multiple comparison test).
Fak Inhibitor 14, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fak+inhibitor+14/fak+inhibitor+14/pmc07730285-230-9-12
Average 90 stars, based on 1 article reviews
fak inhibitor 14 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Merck KGaA fak inhibitor 14
Anchorage independence is required for apical-out polarity. (A) MDCK cells were seeded into soft agar. Cells were left untreated or were treated with RhoA activator II. (B) Quantification of colonies formed in the agar assay. Each data point represents the mean (from a minimum of three field of view) from each experimental replicate (three replicate experiments were performed in total) (error bars are overall mean±s.d.). * P <0.05 (paired two-tailed t -test). (C) MDCK cysts were grown in Matrigel for 7 days and then treated with RhoA activator II for 72 h, pre-treated with FAK inhibitor <t>Y15</t> 24 h followed by Y15+Rho Activator II for an additional 48 h, or treated with Rho activator II for 24 h, followed by Y15+Rho activator II for an additional 48 h (post treatment). (D) Quantification of normal, disrupted lumen and eversion for each condition. Each data point represents the mean (expressed as a percentage) of each condition per replicate experiment (minimum of 10 cysts analyzed per condition per experiment, five replicate experiments performed in total; error bars are overall mean±s.d.). ** P <0.01; ns, not significant (two-way ANOVA with Tukey's multiple comparison test).
Fak Inhibitor 14, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fak+inhibitor+14/fak+inhibitor+14/pmc07017032-147-0-6
Average 90 stars, based on 1 article reviews
fak inhibitor 14 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
CureFAKtor Pharmaceuticals LLC fak inhibitor 14 sc-203950/y15
Anchorage independence is required for apical-out polarity. (A) MDCK cells were seeded into soft agar. Cells were left untreated or were treated with RhoA activator II. (B) Quantification of colonies formed in the agar assay. Each data point represents the mean (from a minimum of three field of view) from each experimental replicate (three replicate experiments were performed in total) (error bars are overall mean±s.d.). * P <0.05 (paired two-tailed t -test). (C) MDCK cysts were grown in Matrigel for 7 days and then treated with RhoA activator II for 72 h, pre-treated with FAK inhibitor <t>Y15</t> 24 h followed by Y15+Rho Activator II for an additional 48 h, or treated with Rho activator II for 24 h, followed by Y15+Rho activator II for an additional 48 h (post treatment). (D) Quantification of normal, disrupted lumen and eversion for each condition. Each data point represents the mean (expressed as a percentage) of each condition per replicate experiment (minimum of 10 cysts analyzed per condition per experiment, five replicate experiments performed in total; error bars are overall mean±s.d.). ** P <0.01; ns, not significant (two-way ANOVA with Tukey's multiple comparison test).
Fak Inhibitor 14 Sc 203950/Y15, supplied by CureFAKtor Pharmaceuticals LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fak+inhibitor+14/fak+inhibitor+14+sc+203950+y15/pm25113248-133-0-10
Average 90 stars, based on 1 article reviews
fak inhibitor 14 sc-203950/y15 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier



Image Search Results


Anchorage independence is required for apical-out polarity. (A) MDCK cells were seeded into soft agar. Cells were left untreated or were treated with RhoA activator II. (B) Quantification of colonies formed in the agar assay. Each data point represents the mean (from a minimum of three field of view) from each experimental replicate (three replicate experiments were performed in total) (error bars are overall mean±s.d.). * P <0.05 (paired two-tailed t -test). (C) MDCK cysts were grown in Matrigel for 7 days and then treated with RhoA activator II for 72 h, pre-treated with FAK inhibitor Y15 24 h followed by Y15+Rho Activator II for an additional 48 h, or treated with Rho activator II for 24 h, followed by Y15+Rho activator II for an additional 48 h (post treatment). (D) Quantification of normal, disrupted lumen and eversion for each condition. Each data point represents the mean (expressed as a percentage) of each condition per replicate experiment (minimum of 10 cysts analyzed per condition per experiment, five replicate experiments performed in total; error bars are overall mean±s.d.). ** P <0.01; ns, not significant (two-way ANOVA with Tukey's multiple comparison test).

Journal: Journal of Cell Science

Article Title: Apical-out polarity in epithelial spheroids requires α6β4 integrins, cell proliferation and anchorage independence

doi: 10.1242/jcs.264323

Figure Lengend Snippet: Anchorage independence is required for apical-out polarity. (A) MDCK cells were seeded into soft agar. Cells were left untreated or were treated with RhoA activator II. (B) Quantification of colonies formed in the agar assay. Each data point represents the mean (from a minimum of three field of view) from each experimental replicate (three replicate experiments were performed in total) (error bars are overall mean±s.d.). * P <0.05 (paired two-tailed t -test). (C) MDCK cysts were grown in Matrigel for 7 days and then treated with RhoA activator II for 72 h, pre-treated with FAK inhibitor Y15 24 h followed by Y15+Rho Activator II for an additional 48 h, or treated with Rho activator II for 24 h, followed by Y15+Rho activator II for an additional 48 h (post treatment). (D) Quantification of normal, disrupted lumen and eversion for each condition. Each data point represents the mean (expressed as a percentage) of each condition per replicate experiment (minimum of 10 cysts analyzed per condition per experiment, five replicate experiments performed in total; error bars are overall mean±s.d.). ** P <0.01; ns, not significant (two-way ANOVA with Tukey's multiple comparison test).

Article Snippet: Focal adhesion kinase (FAK) inhibitor Y15 (also known as FAK inhibitor 14) was used at a final concentration of 2.5 μM (Medchem express, catalog HY-12444).

Techniques: Two Tailed Test, Comparison